Schering suffers delay on Zevalin EU launch
This article was originally published in Clinica
German company Schering is to delay the launch of its radioimmunotherapy product Zevalin (90Y-ibritumomab tiuxetan) in the EU because of certain technical compliance issues. The Berlin-based company, which had planned to launch the product in the second half of 2002, says it is examining all options to release the product as quickly as possible - hopefully in the second half of 2003. Zevalin is the first radioimmunotherapy treatment for certain Non-Hodgkins Lymphoma. Schering stressed that the clinical efficacy of the product was not in question.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.